Imagion Biosystems Limited Appendix 4E for the year ended 31 December 2017 has been lodged with ASX under Listing Rule 4.3A.
Download FY 2017 Appendix 4E and Financial Report
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance